
## Title: COMBINATION DRUG THERAPY FOR TREATING HYPERTENSION

Inventor(s): Carl J. Pepine et al. DOCKET NO.: 028685-0104

1/5


FIGURE 1



Inventor(s): Carl J. Pepine et al. DOCKET NO.: 028685-0104

2/5

FIGURE 2




There were no significant differences in systolic or diastolic blood pressure.

Inventor(s): Carl J. Pepine et al. DOCKET NO.: 028685-0104

3/5

FIGURE 3



The relative risk was 0.98 (95% confidence interval, 0.90-1.06).




	Calcium Strate	Calcium Antagonist Stratogy (CAS) (n = 11267)	Non-Calcium Antagonist Strategy (NCAS) (n = 11309)	n Antagonist (NCAS) 1309)			
						-	
	No. (%)	Rate per 1000 Patient-Years	No. (%)	Rate per 1000 Patient-Years	P Vetue	RR (95% CI)	Fevors CAS Fevors NCAS
First Event	1119 (9.93)	88	1150 (10.17)	37	.57	0.98 (0.90-1.06)	Ī
Death	673 (7.75)	83	883 (7.80)	83	.72	0.98 (0.90-1.07)	Ī
Nordatal Myccardial Infarction	151 (1.34)	.s	153 (1.35)	ĸ	86.	0.99 (0.79-1.24)	
Nordatal Stroke	131 (1.18)	4	148 (1.31)	10	S,	0.89 (0.70-1.12)	
Cardiovascutar-Related Death	431 (3.83)	4	431 (3.81)	4	¥,	1.00 (0.88-1.14)	Ī
Cardlovescular-Related Hospitalization	728 (6.44)	. 72	709 (8.27)	ន	<b>8</b>	1.03 (0.93-1.14)	Ţ
							0.6 0.8 1.0 1.2 1.4
							RR (95% CJ)

Ci indicates confidence interval; RR, relative risk. P value from Kaplan-Meler survival analysis.

Inventor(s): Carl J. Pepine et al. DOCKET NO.: 028685-0104

5/5



Other race/ethnicity indicates Asian or multiracial. All medical conditions were present at baseline. Cl indicates confidence interval; RR, relative risk

FIGURE 5